How Much Further Can AstraZeneca plc, Unilever plc And Rolls-Royce Holding PLC Fall?

Is it time to load up on AstraZeneca plc (LON: AZN), Unilever plc (LON: ULVR) and Rolls-Royce Holding PLC (LON: RR)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What do you do when quality shares fall in price without the company itself doing anything wrong? If you’re a long-term investor, you buy, of course!

Look at drugs giant AstraZeneca (LSE: AZN). It was out of favour for a while when both it and rival GlaxoSmithKline were hit by the loss of patents on key products and increasing generic competition, but investors took a quick shine to new boss Pascal Soriot and his back-to-basics turnaround plan and the share price started picking up again.

But with the latest China-led stock market crunch, we’ve seen AstraZeneca shares turn tail once more — the price is down more than 8% in just the past five days, to 3,964p, and it’s fallen 18% since 2015’s high point in April. The price fall brings AstraZeneca’s forward P/E based on 2016 forecasts down to 15, which looks cheap around the expected bottom in the earnings cycle, especially with a 4.4% dividend yield forecast.

If you thought AstraZeneca was worth buying a week ago, then surely it’s a better bargain now, isn’t it?

Time to clean up?

Unilever (LSE: ULVR) is another stalwart whose price has dipped, with a loss of 13% since 6 August, to 2,572p as I write. To be fair, Unilever does sell a fair bit of its soapy things in the Asian region, but slowing Chinese growth is unlikely to cause any real upset. With EPS predicted to grow at 10% this year, Unilever shares are now on a forward P/E of around 20 — though forecasts could be downgraded a little.

Unilever always looks too highly priced to me and I fear there could be a little more downside yet, but solid defensive stocks are often afforded such premiums by institutional investors. So if you’re looking to pick up such shares in the dips, now could be your chance.

One attraction of Unilever is its dividends, and the share price fall has upped the forecast yields to 3.2% and 3.4% for this year and next. It’s not one of the biggest yields on the market, but it should be well covered by earnings and is generally considered very reliable.

Aerospace bargain?

Rolls-Royce (LSE: RR) shares have been falling after the company that has traditionally just kept on growing its earnings shocked the market with a string of profit warnings. From a peak of nearly £13 in January 2014, the shares have lost a whopping 44% to trade at 721p as I write – a little up from the 685.5p low hit on Monday in the immediate wake of the China crash.

There’s still a couple of years of earnings falls forecast for Rolls-Royce, but with a 2016 P/E of 16 and with dividends set to yield a decently-covered 3% or so, this looks like another that could be undervalued at the bottom of a cycle.

The fundamental nature of these three is unaffected by this week’s market fallout, and they’re just the same companies they were last week — but there will still be people selling out in fear of further irrational panic.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns and has recommended Unilever, and has recommended Glaxo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two white male workmen working on site at an oil rig
Investing Articles

With three new value-boosting strategies in place, BP’s share price looks a bargain to me

A major valuation gap between BP’s share price and its key rivals could close due to three new strategies being…

Read more »

Investing Articles

At 415p, has the Rolls-Royce share price become a bit of a joke?

I think investing should be taken seriously. But has the recent surge in the Rolls-Royce share price turned the engineering…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

How Warren Buffett got rich (and how to aim for something similar)

Warren Buffett’s success is partly the result of good fortune. But even without this, investing in the stock market can…

Read more »

Investing Articles

£10k in cash? Here’s how I’d aim to turn that into annual passive income of £27,000

Our writer explains how he'd invest £10k into dividend shares via an ISA with the goal of building up a…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Down over 15% this year, but is boohoo a buy at today’s share price?

Should I buy boohoo now while the share price is low and aim to sell high later if the business…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 dirt cheap growth stocks with heaps of potential!

These two growth stocks are currently trading some way below their highs, but they've also got bags of potential. Dr…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

3 of the best FTSE 100 stocks to consider in May

FTSE stocks are back in fashion as investors look for undervalued shares. Here are some our writer Royston Wild thinks…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

£7,000 in savings? Here’s what I’d do to turn that into a £1,160 monthly passive income

With some careful consideration, it's possible to make an excellent passive income for life with UK shares. This is how…

Read more »